Drug Profile
Research programme: antibacterials - ActivBiotics
Alternative Names: ABI-0043; Rifamycin derivatives - ActivBioticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ActivBiotics
- Class Rifamycins; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA
- 02 Apr 2008 Preclinical trials in Bacterial infections in USA (unspecified route)